Exact Mass: 389.177556
Exact Mass Matches: 389.177556
Found 500 metabolites which its exact mass value is equals to given mass value 389.177556
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Balofloxacin
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors
Cilazprilat
C20H27N3O5 (389.19506120000005)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
Diphemanil Methylsulfate
C21H27NO4S (389.1660702000001)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics Diphemanil methylsulfate is a quaternary ammonium anticholinergic. It binds muscarinic acetycholine receptors and thereby decreases secretory excretion of stomach acids as well as saliva and sweat. IC50 value: Target: mAChR Diphemanil Methylsulfate exerts its action by primarily binding the muscarinic M3 receptor. M3 receptors are located in the smooth muscles of the blood vessels, as well as in the lungs. This means they cause vasodilation and bronchoconstriction. They are also in the smooth muscles of the gastrointestinal tract (GIT), which help in increasing intestinal motility and dilating sphincters. The M3 receptors are also located in many glands which help to stimulate secretion in salivary glands and other glands of the body.
isoroquefortine C
Roquefortine
Roquefortine is found in milk and milk products. Roquefortine is a metabolite of Penicillium roquefortii, Penicillium commune, Penicillium cyclopium, Penicillium farinosum and many other Penicillium species Common constituent of blue chees. Roquefortine. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=58735-64-1 (retrieved 2024-10-11) (CAS RN: 58735-64-1). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists SCH442416 is a potent, selective and brain-penetrant antagonist of adenosine A2A receptor (A2AR), with Kis of 0.048 and 0.5 nM for human and rat A2AR respectively. SCH442416 displays more than 23000-fold selectivity over A1R, A2BR, and A3R (Ki=1111, 10000, and 10000 nM, respectively). SCH442416 can be used for imaging of adenosine A2A receptors in rat and primate brain[1][2].
Balofloxacin
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors
Cytidine, 2'-deoxy-2',2'-difluoro-N-(1-oxo-2-propylpentyl)-
C17H25F2N3O5 (389.17621840000004)
Ilginatinib
Reproterol
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
3-(benzoyloxy-phenyl-methyl)-1-methyl-4-(1-methyl-1H-imidazol-4-yl)-pyrrolidin-2-one|Cynodin|cynodine
N-[(3R,7R)-(-)-jasmonoyl]-(S)-dopa
C21H27NO6 (389.18382820000005)
(3E,6S)-3-(1H-imidazol-5-ylmethylidene)-6-{[1-(3-methylbut-2-en-1-yl)-1H-indol-3-yl]methyl}piperazine-2,5-dione|tryhistatin
6,7-O,O-dimethyl-N-deacetylisoipecoside aglycon
C21H27NO6 (389.18382820000005)
Ala Ala Asp Asn
Ala Ala Asn Asp
Ala Ala Gln Thr
Ala Ala Thr Gln
Ala Asp Ala Asn
Ala Asp Gly Lys
Ala Asp Gly Gln
Ala Asp Lys Gly
Ala Asp Asn Ala
Ala Asp Gln Gly
Ala Glu Gly Asn
Ala Glu Asn Gly
Ala Gly Asp Lys
Ala Gly Asp Gln
Ala Gly Glu Asn
Ala Gly Gly Trp
Ala Gly Lys Asp
Ala Gly Asn Glu
Ala Gly Gln Asp
Ala Gly Trp Gly
Ala Lys Asp Gly
Ala Lys Gly Asp
Ala Asn Ala Asp
Ala Asn Asp Ala
Ala Asn Glu Gly
Ala Asn Gly Glu
Ala Asn Ser Val
Ala Asn Val Ser
Ala Gln Ala Thr
Ala Gln Asp Gly
Ala Gln Gly Asp
Ala Gln Thr Ala
Ala Ser Asn Val
Ala Ser Val Asn
Ala Thr Ala Gln
Ala Thr Gln Ala
Ala Val Asn Ser
Ala Val Ser Asn
Ala Trp Gly Gly
Asp Ala Ala Asn
Asp Ala Gly Lys
Asp Ala Gly Gln
Asp Ala Lys Gly
Asp Ala Asn Ala
Asp Ala Gln Gly
Asp Gly Ala Lys
Asp Gly Ala Gln
Asp Gly Lys Ala
Asp Gly Gln Ala
Asp Lys Ala Gly
Asp Lys Gly Ala
Asp Asn Ala Ala
Asp Gln Ala Gly
Asp Gln Gly Ala
Glu Ala Gly Asn
Glu Ala Asn Gly
Glu Gly Ala Asn
Glu Gly Gly Lys
Glu Gly Gly Gln
Glu Gly Lys Gly
Glu Gly Asn Ala
Glu Gly Gln Gly
Glu Lys Gly Gly
Glu Asn Ala Gly
Glu Asn Gly Ala
Glu Gln Gly Gly
Gly Ala Asp Lys
Gly Ala Asp Gln
Gly Ala Glu Asn
Gly Ala Gly Trp
Gly Ala Lys Asp
Gly Ala Asn Glu
Gly Ala Gln Asp
Gly Ala Trp Gly
Gly Asp Ala Lys
Gly Asp Ala Gln
Gly Asp Lys Ala
Gly Asp Gln Ala
Gly Glu Ala Asn
Gly Glu Gly Lys
Gly Glu Lys Gly
Gly Gly Ala Trp
Gly Gly Glu Lys
Gly Gly Trp Ala
Gly Ile Asn Ser
Gly Ile Ser Asn
Gly Lys Ala Asp
Gly Lys Asp Ala
Gly Lys Glu Gly
Gly Leu Asn Ser
Gly Leu Ser Asn
Gly Asn Ile Ser
Gly Asn Leu Ser
Gly Asn Ser Ile
Gly Asn Ser Leu
Gly Asn Thr Val
Gly Asn Val Thr
Gly Gln Ser Val
Gly Gln Val Ser
Gly Ser Ile Asn
Gly Ser Leu Asn
Gly Ser Asn Ile
Gly Ser Asn Leu
Gly Ser Gln Val
Gly Ser Val Gln
Gly Thr Asn Val
Gly Thr Val Asn
Gly Val Asn Thr
Gly Val Gln Ser
Gly Val Ser Gln
Gly Val Thr Asn
Gly Trp Ala Gly
Gly Trp Gly Ala
Ile Gly Asn Ser
Ile Gly Ser Asn
Ile Asn Gly Ser
Ile Asn Ser Gly
Ile Ser Gly Asn
Ile Ser Asn Gly
Lys Ala Asp Gly
Lys Ala Gly Asp
Lys Asp Ala Gly
Lys Asp Gly Ala
Lys Glu Gly Gly
Lys Gly Ala Asp
Lys Gly Asp Ala
Lys Gly Glu Gly
Leu Gly Asn Ser
Leu Gly Ser Asn
Leu Asn Gly Ser
Leu Asn Ser Gly
Leu Ser Gly Asn
Leu Ser Asn Gly
Asn Ala Ser Val
Asn Ala Val Ser
Asn Gly Ile Ser
Asn Gly Leu Ser
Asn Gly Ser Ile
Asn Gly Ser Leu
Asn Gly Thr Val
Asn Gly Val Thr
Asn Ile Gly Ser
Asn Ile Ser Gly
Asn Leu Gly Ser
Asn Leu Ser Gly
Asn Ser Ala Val
Asn Ser Gly Ile
Asn Ser Gly Leu
Asn Ser Ile Gly
Asn Ser Leu Gly
Asn Ser Val Ala
Asn Thr Gly Val
Asn Thr Val Gly
Asn Val Ala Ser
Asn Val Gly Thr
Asn Val Ser Ala
Asn Val Thr Gly
Gln Ala Ala Thr
Gln Ala Thr Ala
Gln Gly Ser Val
Gln Gly Val Ser
Gln Ser Gly Val
Gln Ser Val Gly
Gln Thr Ala Ala
Gln Val Gly Ser
Gln Val Ser Gly
Ser Ala Asn Val
Ser Ala Val Asn
Ser Gly Ile Asn
Ser Gly Leu Asn
Ser Gly Asn Ile
Ser Gly Asn Leu
Ser Gly Gln Val
Ser Gly Val Gln
Ser Ile Gly Asn
Ser Ile Asn Gly
Ser Leu Gly Asn
Ser Leu Asn Gly
Ser Asn Ala Val
Ser Asn Gly Ile
Ser Asn Gly Leu
Ser Asn Ile Gly
Ser Asn Leu Gly
Ser Asn Val Ala
Ser Gln Gly Val
Ser Gln Val Gly
Ser Val Ala Asn
Ser Val Gly Gln
Ser Val Asn Ala
Ser Val Gln Gly
Thr Ala Ala Gln
Thr Ala Gln Ala
Thr Gly Asn Val
Thr Gly Val Asn
Thr Asn Gly Val
Thr Asn Val Gly
Thr Gln Ala Ala
Thr Val Gly Asn
Thr Val Asn Gly
Val Ala Asn Ser
Val Ala Ser Asn
Val Gly Asn Thr
Val Gly Gln Ser
Val Gly Ser Gln
Val Gly Thr Asn
Val Asn Ala Ser
Val Asn Gly Thr
Val Asn Ser Ala
Val Asn Thr Gly
Val Gln Gly Ser
Val Gln Ser Gly
Val Ser Ala Asn
Val Ser Gly Gln
Val Ser Asn Ala
Val Ser Gln Gly
Val Thr Gly Asn
Val Thr Asn Gly
Trp Ala Gly Gly
Trp Gly Ala Gly
Trp Gly Gly Ala
ZM 336372
ZM 336372 is a potent inhibitor of the protein kinase c-Raf. The IC50 value is 0.07 μM in the standard assay, which contains 0.1 mM ATP.
Roquefortine
N-jasmonoyl-L-dopa
C21H27NO6 (389.18382820000005)
icas#2
C21H27NO6 (389.18382820000005)
GSK-J1
LY2334737
C17H25F2N3O5 (389.17621840000004)
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor
Diphenyl(1-propoxy)essigsaeure-piperid-4-yl-esterhydrochlorid
C22H28ClNO3 (389.17576080000003)
Urea, N-[2-[(3-cyano-6,8-dimethyl-2-quinolinyl)amino]ethyl]-N-(2-methoxyphenyl)- (9CI)
3-(3,4-DIETHOXY-PHENYL)-6-(4-METHOXY-PHENYL)-PYRAZOLO[1,5-A]PYRIMIDINE
3-Quinolinecarboxylic acid, 1-cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-(3-Methyl-1-piperazinyl)-4-oxo-
PHENYL (4-(4-(4-HYDROXYPHENYL)PIPERAZIN-1-YL)PHENYL)CARBAMATE
2-({2-[4-(1H-Indazol-3-yl)-1-piperazinyl]ethyl}amino)-4(3H)-quina zolinone
(2R)-2-[4-[(4-chlorophenyl)methyl]-5-methyl-1,2,4-triazol-3-yl]-N-pentan-3-ylpyrrolidine-1-carboxamide
C20H28ClN5O (389.19822680000004)
ISO-PROPYL 2-ACETAMIDO-3,4,6-TRI-O-ACETYL-2-DEOXY-BETA-D-GLUCOPYRANOSIDE
C17H27NO9 (389.16857319999997)
Solcitinib
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C308 - Immunotherapeutic Agent > C574 - Immunosuppressant
N-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-N,N,N-trimethyl-1,3-propanediamine
C21H28ClN3S (389.1692358000001)
(R)-Methyl 2-(2-((tert-butoxycarbonyl)amino)-2-Methylpropanamido)-3-(1H-indol-3-yl)propanoate
C20H27N3O5 (389.19506120000005)
2-SEC-BUTYL-4,6-DINITROPHENOL TRIETHANOLAMINE SALT
Ethyl 3-amino-2-{[(2-carbamoyl-4-biphenylyl)methyl]amino}benzoat e
(R)-2-(2-((TERT-BUTOXYCARBONYL)AMINO)-2-METHYLPROPANAMIDO)-3-(1H-INDOL-3-YL)PROPANOIC ACID
C20H27N3O5 (389.19506120000005)
N-[[3-[4-[4-(2-Cyanoethyl)-1-piperazinyl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide
C19H24FN5O3 (389.18630859999996)
Venglustat
D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
Brepocitinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C308 - Immunotherapeutic Agent
Ilginatinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C125450 - JAK2 Inhibitor
1H-2-Benzoxacyclotetradecin-1,7(8H)-dione, 14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)-
C21H27NO6 (389.18382820000005)
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C69145 - Mitogen-Activated Protein Kinase Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor
3-[[2-(3-Pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid
Reproterol
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
N-(4-methoxy-1-methylindazol-3-yl)-1-phenyl-5-propylpyrazole-4-carboxamide
(2E,4E)-5-[(1R,7S,8R,9R)-7-hydroxy-4-methoxycarbonyl-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoate
methyl (2R,3R,4S)-4-[[(1S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethenyl-2-hydroxy-3,4-dihydro-2H-pyran-5-carboxylate
C21H27NO6 (389.18382820000005)
L-alanyl-gamma-D-glutamyl-meso-diaminopimelate(1-)
[(3aR,4S,9bR)-8-(3-fluorophenyl)-1-(pyridin-4-ylmethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
Glu-Glu-Ile
A tripeptide composed of two L-glutamic acid units and L-isoleucine joined in sequence by peptide linkages.
4-[3-(2,5-Dimethyl-1-pyrrolyl)-4-(1-pyrrolidinyl)phenyl]sulfonylmorpholine
C20H27N3O3S (389.1773032000001)
(3aS)-2-m-anisyl-10,10-dimethyl-4,9-dihydro-3aH-imidazo[1,5-b]-carboline-1,3-quinone
3-[1-[Oxo-(1-phenylcyclopropyl)methyl]-4-piperidinyl]-5-phenyl-1,3,4-oxadiazol-2-one
3-(4-fluorophenyl)-N-[3-(1-imidazolyl)propyl]-1-phenyl-4-pyrazolecarboxamide
3-[2-(2,4-Dimethyl-3-furanyl)-2-oxoethyl]-3-hydroxy-1-(2-phenylethyl)-2-indolone
C24H23NO4 (389.16269980000004)
5-[[1-(2-Methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]methyl]-2-methylthiazole
C23H23N3OS (389.15617480000003)
(11aS)-2-(4-methoxybenzyl)-5,5-dimethyl-5,6,11,11a-tetrahydro-1H-imidazo[1,5:1,6]pyrido[3,4-b]indole-1,3(2H)-dione
(15R)-13-[(3-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione
(15R)-13-[(4-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione
(15S)-13-[(2-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione
(15R)-13-[(2-Methoxyphenyl)methyl]-10,10-dimethyl-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione
[(3aS,4S,9bS)-8-(3-fluorophenyl)-1-(pyridin-4-ylmethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
[(3aR,4R,9bR)-8-(3-fluorophenyl)-1-(pyridin-4-ylmethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-4-yl]methanol
(5Z)-5-{(2E)-3-[4-(dimethylamino)phenyl]prop-2-en-1-ylidene}-1-(3,5-dimethylphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
4-hydroxy-6,7-dimethoxy-2-oxo-N-[3-(1-piperidinyl)propyl]-1H-quinoline-3-carboxamide
C20H27N3O5 (389.19506120000005)
2-[(2R,4aS,12aS)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
2-[(2S,4aS,12aS)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
2-[(2S,4aR,12aS)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
2-[(2R,4aR,12aR)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
2-[(2R,4aS,12aR)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
(6S,7R,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
4-[4-[(6S,7S,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6S,7R,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6R,7S,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6S,7R,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-(pyridin-4-ylmethylamino)ethyl]-3,6-dihydro-2H-pyran-3-yl]-4-oxanecarboxamide
C20H27N3O5 (389.19506120000005)
2-[(2R,4aR,12aS)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
2-[(2S,4aS,12aR)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
2-[(2S,4aR,12aR)-8-acetamido-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-ethylacetamide
C20H27N3O5 (389.19506120000005)
(1R,5S)-N-(3-fluorophenyl)-7-[4-(5-pyrimidinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide
(6R,7S,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8S)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-8-(hydroxymethyl)-4-(1-oxopropyl)-7-[4-[2-(3-pyridinyl)ethynyl]phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
4-[4-[(6R,7R,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6R,7S,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6R,7R,8R)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
4-[4-[(6S,7S,8S)-8-(hydroxymethyl)-2-oxo-4-(1-oxopropyl)-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]benzonitrile
Cilazaprilat
C20H27N3O5 (389.19506120000005)
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
SCH 442416
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists SCH442416 is a potent, selective and brain-penetrant antagonist of adenosine A2A receptor (A2AR), with Kis of 0.048 and 0.5 nM for human and rat A2AR respectively. SCH442416 displays more than 23000-fold selectivity over A1R, A2BR, and A3R (Ki=1111, 10000, and 10000 nM, respectively). SCH442416 can be used for imaging of adenosine A2A receptors in rat and primate brain[1][2].
AKT-IN-6
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1).
SIRT-IN-1
SIRT-IN-1 is a potent inhibitor of SIRT1/2/3, with IC50s of 15, 10, 33 μM, respectively.
(1r,9r,10s)-10-hydroxy-4,5,12,13-tetramethoxy-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,12-tetraen-11-one
C21H27NO6 (389.18382820000005)
(1s,2s,4r,7s,11r,14r,16s)-16-(dimethylamino)-14-(prop-1-en-2-yl)-8-(propan-2-ylidene)-3,6,15-trioxatetracyclo[9.3.1.1⁴,⁷.0²,⁴]hexadecane-5,9,12-trione
C21H27NO6 (389.18382820000005)
methyl (2e,3e,5e,9e)-11-{2,4-dihydroxy-4-methyl-6-oxa-3-azabicyclo[3.1.0]hex-2-en-1-yl}-2-ethylidene-4,10-dimethyl-11-oxoundeca-3,5,9-trienoate
C21H27NO6 (389.18382820000005)
[1-methyl-4-(1-methylimidazol-4-yl)-2-oxopyrrolidin-3-yl](phenyl)methyl benzoate
(1s,8s,10s,11r,12s)-3,4,11,12-tetramethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.1⁸,¹¹.0¹,¹⁰.0²,⁷]octadeca-2,4,6-trien-13-one
C21H27NO6 (389.18382820000005)
(1s,8s,10s,11r,12r)-3,4,11,12-tetramethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.1⁸,¹¹.0¹,¹⁰.0²,⁷]octadeca-2,4,6-trien-13-one
C21H27NO6 (389.18382820000005)
(1s,4z,9r)-6-hydroxy-4-(3h-imidazol-4-ylmethylidene)-9-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
3-[(2s,5s,8s)-5-benzyl-3,6,9-trihydroxy-8-(2-methylpropyl)-5,8-dihydro-2h-1,4,7-triazonin-2-yl]propanoic acid
C20H27N3O5 (389.19506120000005)
6-hydroxy-4-(1h-imidazol-4-ylmethylidene)-9-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
(1s,4z,7s,9r)-6-hydroxy-4-(3h-imidazol-4-ylmethylidene)-9-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
12,13-dihydroxy-14-oxo-7,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadecan-4-yl 1h-pyrrole-2-carboxylate
C20H27N3O5 (389.19506120000005)
(2s,3r,4r,5r,6s)-2-({6-[(z)-(hydroxyimino)methyl]-[2,2'-bipyridin]-4-yl}oxy)-3,5-dimethoxy-6-methyloxan-4-ol
(4r,7r)-4-[(2s)-butan-2-yl]-6-hydroxy-7-isopropyl-4,12-dimethoxy-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
C20H27N3O5 (389.19506120000005)
(2s)-4-[(2s,4s)-1,8-dihydroxy-2,4-dimethyloct-6-en-1-ylidene]-5-hydroxy-2-[(s)-hydroxy(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
C21H27NO6 (389.18382820000005)
10-hydroxy-4,5,12,13-tetramethoxy-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,12-tetraen-11-one
C21H27NO6 (389.18382820000005)
(1r,2s,4s,9r,10r,12r,13s)-12,13-dihydroxy-14-oxo-7,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadecan-4-yl 1h-pyrrole-2-carboxylate
C20H27N3O5 (389.19506120000005)
4,11'-dimethyl-3'-(4-methyl-5-oxooxolan-2-yl)-13'-oxa-2'-azaspiro[oxolane-2,7'-tricyclo[8.3.0.0²,⁶]tridecan]-10'-ene-5,12'-dione
C21H27NO6 (389.18382820000005)
(4z)-6-hydroxy-4-(3h-imidazol-4-ylmethylidene)-9-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
3,4,11,12-tetramethoxy-17-methyl-18-oxa-17-azapentacyclo[8.4.3.1⁸,¹¹.0¹,¹⁰.0²,⁷]octadeca-2,4,6-trien-13-one
C21H27NO6 (389.18382820000005)
(2s,10r,12s)-6,13-dihydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
n-(2-{2-[(4-hydroxy-1-methyl-2-oxoquinolin-3-yl)methyl]-1h-indol-3-yl}ethyl)ethanimidic acid
(1's,2s,3's,4r,6's)-4,11'-dimethyl-3'-[(2s,4s)-4-methyl-5-oxooxolan-2-yl]-13'-oxa-2'-azaspiro[oxolane-2,7'-tricyclo[8.3.0.0²,⁶]tridecan]-10'-ene-5,12'-dione
C21H27NO6 (389.18382820000005)
(1r,4z,7r,9s)-6-hydroxy-4-(3h-imidazol-4-ylmethylidene)-9-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
4-(1,8-dihydroxy-2,4-dimethyloct-6-en-1-ylidene)-5-hydroxy-2-[hydroxy(4-hydroxyphenyl)methyl]-2h-pyrrol-3-one
C21H27NO6 (389.18382820000005)
6,13-dihydroxy-10-(2-methylbut-3-en-2-yl)-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaen-21-one
5-hydroxy-3-(1h-imidazol-4-ylmethylidene)-6-{[1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-1,6-dihydropyrazin-2-one
(1s,2s,4s,9s,10r,12r,13s)-12,13-dihydroxy-14-oxo-7,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadecan-4-yl 1h-pyrrole-2-carboxylate
C20H27N3O5 (389.19506120000005)
2-({6-[(hydroxyimino)methyl]-[2,2'-bipyridin]-4-yl}oxy)-3,5-dimethoxy-6-methyloxan-4-ol
(1s,4e,7s,9r)-6-hydroxy-4-(3h-imidazol-4-ylmethylidene)-9-(2-methylbut-3-en-2-yl)-2,5,16-triazatetracyclo[7.7.0.0²,⁷.0¹⁰,¹⁵]hexadeca-5,10,12,14-tetraen-3-one
(3s)-3-{[6-hydroxy-1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-3h-1,4-benzodiazepine-2,5-diol
(2s)-3-(3,4-dihydroxyphenyl)-2-({1-hydroxy-2-[(1r,2r)-3-oxo-2-[(2z)-pent-2-en-1-yl]cyclopentyl]ethylidene}amino)propanoic acid
C21H27NO6 (389.18382820000005)
3-{[6-hydroxy-1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-3h-1,4-benzodiazepine-2,5-diol
(s)-[(3s,4r)-1-methyl-4-(1-methylimidazol-4-yl)-2-oxopyrrolidin-3-yl](phenyl)methyl benzoate
(3e,6s)-3-(3h-imidazol-4-ylmethylidene)-6-{[1-(3-methylbut-2-en-1-yl)indol-3-yl]methyl}-6h-pyrazine-2,5-diol
3-(3,4-dihydroxyphenyl)-2-({1-hydroxy-2-[3-oxo-2-(pent-2-en-1-yl)cyclopentyl]ethylidene}amino)propanoic acid
C21H27NO6 (389.18382820000005)
(4s,7r)-4-[(2s)-butan-2-yl]-6-hydroxy-7-isopropyl-4,12-dimethoxy-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one
C20H27N3O5 (389.19506120000005)
(1s,9s,10s)-10-hydroxy-4,5,12,13-tetramethoxy-17-methyl-17-azatetracyclo[7.5.3.0¹,¹⁰.0²,⁷]heptadeca-2,4,6,12-tetraen-11-one
C21H27NO6 (389.18382820000005)